KLRS

Kalaris Therapeutics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.85
52-Week Range: $2.51 – $11.88
Market Cap: $64.27M
P/E (TTM): —
EPS (TTM): -2.02
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.11
PEG Ratio: —
Return on Equity: -79.91%
Return on Assets: -31.03%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 10.98
Debt/Equity: 0.02
Total Debt: $1.40M
Free Cash Flow: $-26.24M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-27.86M

KLRS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$11.76M	$11.71M	$45.04M	$30.75M
Selling, General & Admin	$2.24M	$1.76M	$6.69M	$15.40M
Operating Expenses	$14.01M	$13.46M	$51.73M	$46.15M
Operating Income	-$14.01M	-$13.46M	-$51.73M	-$46.15M
EBITDA	-$15.25M	-$14.01M	-$66.47M	-$41.98M
Pretax Income	-$15.48M	-$14.70M	-$69.17M	-$43.44M
Net Income	-$15.48M	-$14.70M	-$69.17M	-$43.44M
Diluted EPS	-11.64	-11.05	-3.70	-2.85
Diluted Shares	1.33M	1.33M	18.70M	15.27M

KLRS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$3.06M	$3.17M	$1.64M	$98.05M
Current Assets	$3.90M	$3.33M	$2.61M	$118.81M
Total Assets	$3.90M	$3.33M	$6.16M	$121.74M
Current Liabilities	$5.69M	$3.94M	$24.70M	$9.71M
Long-Term Debt	$3.25M	—	—	—
Total Debt	$3.25M	—	$19.54M	$1.45M
Total Liabilities	$34.17M	$48.35M	$102.78M	$42.92M
Retained Earnings	-$32.70M	-$47.39M	-$116.56M	-$160.00M
Shareholders' Equity	-$30.27M	-$45.02M	-$96.62M	$78.81M
Working Capital	-$1.79M	-$609.00K	-$22.10M	$109.09M
Net Debt	$194.00K	—	$17.90M	—

KLRS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$9.78M	-$14.13M	-$20.67M	-$38.37M
Capital Expenditure	—	—	—	-$200.00K
Free Cash Flow	-$9.78M	-$14.13M	-$20.67M	-$38.57M
Depreciation & Amortisation	—	—	$0.00	$13.00K
Stock-Based Compensation	$271.00K	$148.00K	$895.00K	$1.94M
Investing Cash Flow	—	—	$0.00	-$19.72M
Financing Cash Flow	$12.78M	$14.24M	$19.14M	$155.01M
Net Change in Cash	$3.00M	$110.00K	-$1.53M	$96.91M

KLRS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$6.03M	$8.44M	$9.13M	$7.16M	$7.57M	$9.02M
Selling, General & Admin	$4.32M	$3.82M	$3.62M	$3.64M	$4.26M	$3.37M
Operating Expenses	$10.35M	$12.26M	$12.74M	$10.80M	$11.83M	$12.39M
Operating Income	-$10.35M	-$12.26M	-$12.74M	-$10.80M	-$11.83M	-$12.39M
EBITDA	-$8.75M	-$11.35M	-$11.89M	-$9.99M	-$10.85M	-$11.51M
Pretax Income	-$10.20M	-$11.35M	-$11.89M	-$10.00M	-$10.86M	-$11.52M
Net Income	-$10.20M	-$11.35M	-$11.89M	-$10.00M	-$10.86M	-$11.52M
Diluted EPS	-2.52	-0.61	-0.64	—	-0.46	-0.48
Diluted Shares	4.05M	18.70M	18.70M	—	23.72M	23.80M

KLRS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$100.97M	$88.43M	$42.39M	$98.05M	$34.43M	$43.17M
Current Assets	$102.18M	$91.65M	$78.18M	$118.81M	$98.47M	$95.92M
Total Assets	$103.09M	$92.84M	$81.17M	$121.74M	$109.81M	$99.54M
Current Liabilities	$7.14M	$7.65M	$6.07M	$9.71M	$8.08M	$8.74M
Total Debt	—	—	$1.54M	$1.45M	$1.41M	$1.40M
Total Liabilities	$39.22M	$39.73M	$39.31M	$42.92M	$41.25M	$41.87M
Retained Earnings	-$126.76M	-$138.11M	-$150.00M	-$160.00M	-$170.85M	-$182.37M
Shareholders' Equity	$63.87M	$53.12M	$41.87M	$78.81M	$68.56M	$57.67M
Working Capital	$95.04M	$84.00M	$72.12M	$109.09M	$90.39M	$87.18M

KLRS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$7.44M	-$12.54M	-$11.33M	-$7.06M	-$11.58M	-$11.05M
Capital Expenditure	—	—	—	-$17.00K	—	—
Free Cash Flow	-$7.44M	-$12.54M	-$11.52M	-$7.07M	-$11.58M	-$11.05M
Depreciation & Amortisation	$0.00	$0.00	$3.00K	$10.00K	$10.00K	$10.00K
Stock-Based Compensation	$374.00K	$591.00K	$638.00K	$333.00K	$580.00K	$644.00K
Investing Cash Flow	$0.00	$0.00	-$34.71M	$14.98M	-$50.35M	$20.17M
Financing Cash Flow	$107.27M	$0.00	$0.00	$47.74M	-$1.70M	-$377.00K
Net Change in Cash	$99.83M	-$12.54M	-$46.04M	$55.67M	-$63.63M	$8.75M

Market Snapshot

About

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious medical conditions. The company's pipeline typically addresses unmet medical needs in areas such as oncology, immunology, or rare diseases through innovative drug candidates. Kalaris applies modern drug discovery and development approaches to advance its therapeutic programs through clinical trials. As a development-stage company, it focuses on bringing novel treatments from research into patient care.